Company: OPGN
Filing Date: 2025-08-21
Form Type: 10-K
Source: 0001829126-25-006628
Chunk: 1666

Company: OPGEN INC
Filing Date: 2025-08-21
Form: 10-K
Item: Item 9B
Chunk 1666
---
0.01 par value; 10,000,000 shares authorized; 250 shares issued and outstanding at December 31, 2024 and 2023

    2

    2,500

    Common stock, $0.01 par value; 100,000,000 shares authorized; 10,070,779 and 1,282,686 shares issued and outstanding at December 31, 2024 and 2023, respectively

    100,708

    12,827

    Additional paid-in capital

    300,780,440

    293,991,529

    Accumulated deficit

    (293,500,522
    )

    (305,493,302
    )
  
    Accumulated other comprehensive loss

    -

    (75,138
    )
  
    Total stockholders’ equity (deficit)

    7,380,628

    (11,561,584
    )
  
    Total liabilities and stockholders’ equity (deficit)
     
    $
    9,862,698

    $
    1,882,274

See accompanying notes to consolidated financial statements.

F-5

OpGen, Inc.

Consolidated Statements of Operations and
Comprehensive Income (Loss)

    Year Ended December 31,

    2024

    2023

    Revenue

    Product sales
     
    $
    169,373

    $
    2,400,053

    Laboratory services

    26,776

    153,719

    Listing sponsorship services

    5,000,000

    -

    Collaboration revenue

    -

    864,548

    Total revenue

    5,196,149

    3,418,320

    Operating expenses

    Cost of products sold

    31,636

    3,084,075

    Cost of services

    1,575

    424,939

    Research and development, net

    48,820

    4,732,851

    General and administrative

    4,542,025

    8,081,664

    Sales and marketing

    172,238

    2,783,268

    Impairment of right-of-use asset

    -

    849,243

    Impairment of property and equipment

    -

    1,231,